The Patent Finder

Alpine Immune Sciences, Inc.

31 patents currently held · Updated Nov 18, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Dec 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 22, 2027
    The maintenance fee for PD-L2 variant immunomodulatory proteins and uses thereof (US 11,732,022) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
  • 1 fee due Mar 12, 2027
    The maintenance fee for CTLA-4 Variant Immunomodulatory Proteins and Uses Thereof (US 11,753,458) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
  • 1 fee due Jun 5, 2027
    The maintenance fee for CD112 variant immunomodulatory proteins and uses thereof (US 11,834,490) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 12,486,312Immunomodulatory Proteins with Tunable Affinities
In force
 · High confidence
In forceHigh confidence
US 11,078,282CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,359,022CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,479,609CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,498,967CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,319,359Immunomodulatory Proteins with Tunable Affinities
In force
 · Medium confidence
In forceMedium confidence
US 11,096,988CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,117,948CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,117,949CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,117,950CD80 variant immunomodulatory proteins and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 31 patents shown.
Pro members see all 31.
Pro members: see all 31 patents
Also on record, not counted in the 31: 1 patent in force now held by others · 10 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

11 pending · 2 abandoned · 3 no status recorded

Showing 1 to 10 of 16, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/250,472CTLA-4 Variant Immunomodulatory Proteins and Uses ThereofJun 26, 2025Pending
19/026,270Multi-Domain Immunomodulatory Proteins and Methods of Use ThereofJan 16, 2025Pending
18/895,259April and Baff Inhibitory Immunomodulatory Proteins and Methods of Use ThereofSep 24, 2024Pending
18/895,187April and Baff Inhibitory Immunomodulatory Proteins and Methods of Use ThereofSep 24, 2024Pending
18/821,680Icos Ligand Variant Immunomodulatory Proteins and Uses ThereofAug 30, 2024Pending
18/767,844PD-1 Variant Immunomodulatory Proteins and Uses ThereofJul 9, 2024Pending
18/182,308CD80 Variant Immunomodulatory Proteins and Uses ThereofMar 10, 2023Pending
18/844,376Mar 6, 2023No status recorded
18/289,746Methods of Dosing and Treatment with a Taci-Fc Fusion Immunomodulatory ProteinMay 6, 2022Pending
17/923,208April and Baff Inhibitory Immunomodulatory Proteins with and Without a T Cell Inhibitory Protein and Methods of Use ThereofMay 7, 2021Pending
10 of 16 applications shown.
Pro members see all 16 published applications.
Pro members: see all 16 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited